Lineage Cell Therapeutics, Inc. Deferred Federal Income Tax Expense (Benefit)
Lineage Cell Therapeutics, Inc. (LCTX) reported Deferred Federal Income Tax Expense (Benefit) of -$251.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-05
- Lineage Cell Therapeutics, Inc. deferred federal income tax expense (benefit) for the quarter ending 2017-09-30 was $5.20M.
- Lineage Cell Therapeutics, Inc. deferred federal income tax expense (benefit) for the quarter ending 2017-06-30 was -$3.90M.
- Lineage Cell Therapeutics, Inc. deferred federal income tax expense (benefit) for the quarter ending 2017-03-31 was $3.90M.
- Lineage Cell Therapeutics, Inc. deferred federal income tax expense (benefit) for the quarter ending 2015-12-31 was $1.20M.
- Lineage Cell Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was -$251.00K.
- Lineage Cell Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was $0.00.
- Lineage Cell Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2015 was $4.80M.
- Lineage Cell Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2014 was -$5.20M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 3 month | Deferred Federal Income Tax Expense (Benefit) 3 month as first filed | Deferred Federal Income Tax Expense (Benefit) 6 month | Deferred Federal Income Tax Expense (Benefit) 6 month as first filed | Deferred Federal Income Tax Expense (Benefit) 9 month | Deferred Federal Income Tax Expense (Benefit) 9 month as first filed | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$251.00K 10-K · filed 2026-03-05 | |||||||
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 | |||||||
| 2017-09-30 | $5.20M 10-Q · filed 2017-11-09 | $1.30M derived: sum of 2 quarters · filed 2017-11-09 | $4.80M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | -$3.90M 10-Q · filed 2017-08-09 | $0.00 10-Q · filed 2017-08-09 | ||||||
| 2017-03-31 | $3.90M 10-Q · filed 2018-05-10 | |||||||
| 2015-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $2.20M derived: sum of 2 quarters · filed 2018-03-15 | $3.50M derived: sum of 3 quarters · filed 2018-03-15 | $4.80M 10-K · filed 2018-03-15 | -$4.80M 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $2.30M derived: sum of 2 quarters · filed 2016-11-04 | $3.60M 10-Q · filed 2016-11-04 | -$3.60M 10-Q · filed 2015-11-09 | $2.00M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $2.60M 10-Q · filed 2016-08-09 | -$2.60M 10-Q · filed 2015-08-10 | $1.00M derived: sum of 3 quarters · filed 2017-03-16 | -$160.00K derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | $1.30M 10-Q · filed 2016-05-10 | $1.25M 10-Q · filed 2015-05-08 | -$300.00K derived: sum of 2 quarters · filed 2017-03-16 | -$1.46M derived: sum of 3 quarters · filed 2017-03-16 | -$5.05M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$2.76M derived: sum of 2 quarters · filed 2017-03-16 | -$6.35M derived: sum of 3 quarters · filed 2017-03-16 | -$5.20M 10-K · filed 2017-03-16 | -$5.16M 10-K · filed 2015-03-11 | |||
| 2014-09-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$4.75M derived: sum of 2 quarters · filed 2015-11-09 | -$3.60M 10-Q · filed 2015-11-09 | |||||
| 2014-06-30 | -$3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$2.44M 10-Q · filed 2015-08-10 | ||||||
| 2014-03-31 | $1.15M 10-Q · filed 2015-05-08 | |||||||
| 2013-12-31 | -$2.80M 10-K · filed 2015-03-11 | $2.80M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |